Exee recently posted a link to the January 2012 story of the deal between Constellation and Genentech. Constellation are leaders in epigenetics which is the field for switching genes off and on. There are two points of interest. Firstly, the deal highlighted the importance of MYC as an oncology target;
"MYC is a master regulator of diverse cellular functions and has long been considered a compelling therapeutic target because of its role in many human malignancies including hematologic and solid tumors."
Secondly, by a twist of timing perhaps unbeknown to Exee, the collaboration will soon end. John Carroll from FierceBiotech picks up the story in an article dated January 18, 2015 titled Exclusive: Constellation chops staff, plots go-it-alone strategy as Genentech option deadline looms.
Whether Genentech pursues its option to acquire Constellation is unknown but we do know that drug developers like Genentech are vitally interested in the big ideas around transcription factors and gene regulation. MYC is the granddaddy of them all.
The work by Phylogica on Omomyc is independent of VHIO.
PYC Price at posting:
2.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)